More importantly, SAMD13 expression could be a potential for immuno-checkpoint inhibitor (ICI) treatment, although it exhibits acquired diverse anti-cancer drug resistant in HCC. This evidence concerns the gene SAMD13 and hepatocellular carcinoma.